Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 321

1.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Sep 14. doi: 10.1038/s41375-018-0235-5. [Epub ahead of print]

PMID:
30218008
2.

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Cancer. 2018 Sep 11. doi: 10.1002/cncr.31680. [Epub ahead of print]

PMID:
30204239
3.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.

Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV.

Blood Cancer J. 2018 Aug 29;8(9):86. doi: 10.1038/s41408-018-0110-7.

4.

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK.

Future Oncol. 2018 Aug 23. doi: 10.2217/fon-2018-0275. [Epub ahead of print]

PMID:
30136602
5.

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

Qian G, Yao W, Zhang S, Bajpai R, Hall WD, Shanmugam M, Lonial S, Sun SY.

Cancer Lett. 2018 Oct 28;435:44-54. doi: 10.1016/j.canlet.2018.07.033. Epub 2018 Jul 29.

PMID:
30059709
6.

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S.

Cancer Cell. 2018 Aug 13;34(2):315-330.e7. doi: 10.1016/j.ccell.2018.06.012. Epub 2018 Jul 19.

PMID:
30033091
7.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

Chang A, Nasti TH, Khan MK, Parashar S, Kaufman JL, Boise LH, Lonial S, Ahmed R, Nooka AK.

J Oncol Pract. 2018 Sep;14(9):561-564. doi: 10.1200/JOP.18.00208. Epub 2018 Jul 13. No abstract available.

PMID:
30004825
8.

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S.

J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143.

PMID:
29996069
9.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2018 Jul 2. doi: 10.1038/s41375-018-0196-8. [Epub ahead of print]

PMID:
29967379
10.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

11.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8.

12.

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, Lonial S.

Br J Haematol. 2018 Jun;181(5):628-636. doi: 10.1111/bjh.15248. Epub 2018 May 17.

PMID:
29774521
13.

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J.

Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010.

PMID:
29547721
14.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15122. [Epub ahead of print] No abstract available.

PMID:
29411874
15.

Current developments in immunotherapy in the treatment of multiple myeloma.

Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M.

Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6. Review.

PMID:
29409124
16.

CD86 regulates myeloma cell survival.

Gavile CM, Barwick BG, Newman S, Neri P, Nooka AK, Lonial S, Lee KP, Boise LH.

Blood Adv. 2017 Nov 16;1(25):2307-2319. doi: 10.1182/bloodadvances.2017011601. eCollection 2017 Nov 28.

17.

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, Lokhorst HM, van de Donk NWCJ, Clemens PL, Sasser AK.

Blood Adv. 2017 Oct 24;1(23):2105-2114. doi: 10.1182/bloodadvances.2017006866. eCollection 2017 Oct 24.

18.

TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.

Shah SP, Nooka AK, Lonial S, Boise LH.

Blood Adv. 2017 Sep 26;1(21):1848-1853. doi: 10.1182/bloodadvances.2017006122. eCollection 2017 Sep 26.

19.

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.352. [Epub ahead of print]

20.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS.

Clin Pharmacokinet. 2018 Apr;57(4):529-538. doi: 10.1007/s40262-017-0598-1.

Supplemental Content

Loading ...
Support Center